Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Insulin is necessary for repairing olfactory neurons

    Researchers have known for some time that insulin plays a vital role in regeneration and growth in some types of neurons that relay environmental sensory information to our brains, such as sight. However, they know relatively little about the role of insulin in the sense of smell. Now, investigators at the Monell Chemical Senses Center have shown that insulin plays a critical role in the maturation, after injury, of immature olfactory sensory neurons (OSNs). The team published their findings in eNeuro earlier this month.

  • Rivaroxaban reduces First and Total Ischemic Events in Patients with Peripheral Artery Disease

    Rivaroxaban, in addition to low dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization, a procedure to open blocked arteries in the leg.

  • Clopidogrel Superior to Aspirin for Long Term Post Stent Maintenance

    Patients saw 30 percent reduced risk of adverse events after two years of follow up. Clopidogrel outperformed aspirin in what is believed to be the first and largest randomized trial to compare the effectiveness of the two  antiplatelet drugs as long term maintenance therapy for patients who had no adverse events after one  year of dual antiplatelet therapy (DAPT) following the insertion of a coronary stent.

  • Shilpa Medicare Limited ties up with Dr. Reddys Laboratories Limited for production of Sputnik V vaccine

    Shilpa Biologicals Private Limited, SBPL, has entered into a 3 year DefInitive Agreement with Dr. Reddys Laboratories Limited, DRL, for production supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka.

    The targeted production of the dual vector Sputnik V for the fIrst 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production.

  • American India Foundation to Set up Oxygen Plants Across 25 Cities in India

    American India Foundation (AIF), on Thursday confirmed, that in collaboration with Paytm, Indian Biogas Association, Foundation For Innovation & Research In Science & Technology and Acquafront Infrastructure Pvt. Ltd., it is set to roll out Oxygen Plants in 25 of the most virus-ravaged cities in the country.

  • Dr. Reddys Laboratories enters into a Voluntary Licensing Agreement with Lilly to Expand Access toCOVID-19 Treatment in India

    Dr. Reddys Laboratories Ltd announced that it has entered into a royalty-free, non-exclusive voluntary  licensing agreement with  Eli Lilly and Company for the manufacture and commercialization of the drug, baricitinib,in India.

  • Zydus Cadila entity to sell its India focused Animal Health Business to Multiples Alternate Asset Management led consortium

    Zydus Animal Health and Investments Limited  a wholly owned material subsidiary of Cadila Healthcare Limited, has entered into a Business Transfer Agreement (BTA) and other Ancillary Agreements  to sell and transfer its Animal Healthcare Established Markets Undertaking to Multiples Alternate Asset Management led consortium. Zydus AH is the animal health business of ZAHL focused on India and certain other countries.

  • Dr. Reddys Laboratories announces the launch of Ertapenem for Injection in the U.S. Market

    Dr. Reddys Laboratories Ltd announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA).

  • Karnataka warns Cipla and Jubilant of legal action for less supply of Remdesivir

    The Karnataka government served notices to pharmaceutical majors Cipla and Jubilant warning them of legal proceedings for not supplying adequate quantities of Remdesivir injection bottles as directed by the Government of India. In a notice to the pharmaceutical companies, the Principal Secretary in the Revenue department N Manjunatha Prasad said they were ordered to deliver 62,000 vials of Remdesivir injection, but they supplied very less consignment.

  • Government take steps to ramp up availability of Amphotericin B - to fight Mucormycosis

    A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from Mucormycosis, a post COVID complication. The Government of India is therefore engaging with the manufacturers to ramp up production of the drug. The supply position is expected to improve with extra  imports of this drug and  increase in its production domestically.

Subscribe to Pharma News

Search this website